CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $66.3 million in its fourth quarter.
The Cambridge, Massachusetts-based company said it had a loss of $1.35 per share.
The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.71 per share.
The cancer drug developer posted revenue of $51.5 million in the period, also exceeding Street forecasts. Eight analysts surveyed by Zacks expected $24 million.
For the year, the company reported that its loss widened to $347.7 million, or $7.27 per share. Revenue was reported as $66.5 million.
Blueprint Medicines shares have decreased 19% since the beginning of the year. The stock has dropped 13% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC
Please read our comment policy before commenting.